CLINICAL PHARMACOLOGIC TARGETING W/ FLECAINIDE OF SCN5A GENE MUTATION

氟卡尼针对 SCN5A 基因突变的临床药理学靶向

• 批准号: 6263833
• 负责人: ARTHUR J. MOSS
• 金额: $ 1.48万
• 依托单位: UNIVERSITY OF ROCHESTER
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6263833
• 关键词: antiarrhythmic agent; clinical research; clinical trial phase I; drug screening /evaluation; electrocardiography; gene mutation; heart disorder chemotherapy; human subject; long QT syndrome

This study will look at two patients to evaluate clinical pharmacologic targeting with Flecainide of the CSN5A gene mutation. Preliminary evidence from one patient treated with Flecainide in Nebraska indicates dramatic normalization of the electrocardiogram with shortening of the QT interval to normal following ordinary doses of Flecainide.

本研究将对两例CSN5A基因突变的患者进行临床药理学评价。内布拉斯加州一名接受Flecainide治疗的患者的初步证据表明，在普通剂量的Flecainide治疗后，心电图显著正常化，QT间期缩短至正常。